|Dr. Howard J. Federoff M.D., Ph.D.||CEO, Pres & Director||N/A||N/A||N/A|
|Dr. Monil Shah M.B.A., Pharm.D.||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Kevin A. D'Amour||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Ronald Guido M.S.||Chief Devel. Officer||N/A||N/A||1957|
|Ms. Lynn Sadowski Mason M.S.||Exec. VP of Clinical Operations||N/A||N/A||N/A|
|Mr. Stephen R. Goldberg||Sec.||N/A||N/A||N/A|
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.
Brooklyn ImmunoTherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.